Increasing the Dose and/or Repeating Faecal Microbiota Transplantation (FMT) Increases the Response in Patients with Irritable Bowel Syndrome (IBS)

被引:50
作者
El-Salhy, Magdy [1 ,2 ,3 ]
Hausken, Trygve [2 ,3 ]
Hatlebakk, Jan Gunnar [2 ,3 ]
机构
[1] Stord Hosp, Dept Med, Sect Gastroenterol, Box 4000, N-5409 Stord, Norway
[2] Univ Bergen, Dept Clin Med, N-5007 Bergen, Norway
[3] Natl Ctr Funct Gastrointestinal Disorders, N-5021 Bergen, Norway
关键词
abdominal symptoms; dysbiosis; faecal microbiota transplantation; fatigue; IBS; quality of life; QUALITY-OF-LIFE; GASTROINTESTINAL MICROBIOTA; GUT MICROBIOTA; DYSBIOSIS;
D O I
10.3390/nu11061415
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Faecal microbiome transplantation (FMT) appears to be an effective method for treating irritable bowel syndrome (IBS) patients. However, it is not clear if a high transplant dose and/or repeating FMT are/is needed to ensure a response. The present study was undertaken to clarify this matter. Methods: Ten IBS patients who did not respond to a 30-g transplant subsequently received a 60-g transplant into the duodenum via a gastroscope. The patients provided faecal samples before and 1 month after FMT. They completed five questionnaires measuring symptoms, fatigue and quality of life at baseline and then at 2 weeks, 1 month and 3 months after FMT. The dysbiosis index (DI) was measured using the GA-map Dysbiosis Test((R)). Results: Seven patients (70%) responded to the 60-g transplant, with significant clinical improvements in the abdominal symptoms, fatigue and quality of life in 57%, 80% and 67% of these patients. The 60-g transplant also reduced the DI. Conclusion: FMT is an effective treatment for IBS. A high-dose transplant and/or repeated FMT increase the response rate and the intensity of the effects of FMT.
引用
收藏
页数:10
相关论文
共 39 条
[1]   Quality of life in patients with subjective food hypersensitivity: Applicability of the 10-item short form of the Nepean Dyspepsia Index [J].
Arslan, G ;
Lind, R ;
Olafsson, S ;
Florvaag, E ;
Berstad, A .
DIGESTIVE DISEASES AND SCIENCES, 2004, 49 (04) :680-687
[2]  
BALSARI A, 1982, MICROBIOLOGICA, V5, P185
[3]  
Brandt LJ, 2015, AM J GASTROENTEROL, V110, P18, DOI [10.1038/ajg.2014.395, 10.1038/ajg.2014.295]
[4]   The epidemiology of irritable bowel syndrome [J].
Canavan, Caroline ;
West, Joe ;
Card, Timothy .
CLINICAL EPIDEMIOLOGY, 2014, 6 :71-80
[5]   Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD [J].
Casen, C. ;
Vebo, H. C. ;
Sekelja, M. ;
Hegge, F. T. ;
Karlsson, M. K. ;
Ciemniejewska, E. ;
Dzankovic, S. ;
Froyland, C. ;
Nestestog, R. ;
Engstrand, L. ;
Munkholm, P. ;
Nielsen, O. H. ;
Rogler, G. ;
Simren, M. ;
Ohman, L. ;
Vatn, M. H. ;
Rudi, K. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (01) :71-83
[6]   Factors Affecting Gastrointestinal Microbiome Development in Neonates [J].
Chong, Clara Yieh Lin ;
Bloomfield, Frank H. ;
O'Sullivan, Justin M. .
NUTRIENTS, 2018, 10 (03)
[7]   A Molecular Analysis of Fecal and Mucosal Bacterial Communities in Irritable Bowel Syndrome [J].
Codling, Caroline ;
O'Mahony, Liam ;
Shanahan, Fergus ;
Quigley, Eamonn M. M. ;
Marchesi, Julian R. .
DIGESTIVE DISEASES AND SCIENCES, 2010, 55 (02) :392-397
[8]   Sarcoidosis-associated fatigue [J].
Drent, Marjolein ;
Lower, Elyse E. ;
De Vries, Jolanda .
EUROPEAN RESPIRATORY JOURNAL, 2012, 40 (01) :255-263
[9]  
Drossman DA, 2000, AM J GASTROENTEROL, V95, P999
[10]  
El-Salhy M., 2019, GASTROENTEROLO UNPUB